UniProtKB/Swiss-Prot P11387: Variant p.Asn722Ser

DNA topoisomerase 1
Gene: TOP1
Feedback?

Variant information Variant position:

722 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

US The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Asparagine (N) to Serine (S) at position 722 (N722S, p.Asn722Ser). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Change from medium size and polar (N) to small size and polar (S) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Variant description:

In CPT-resistant leukemia. Any additional useful information about the variant.

Sequence information Variant position:

722 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

765 The length of the canonical sequence.
Location on the sequence:

EVQATDREENKQIALGTSKL N YLDPRITVAWCKKWGVPIEK The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         EVQATDREENKQIALGTSKLNYLDPRITVAWCKKWGVPIEK

Mouse                         EVQATDREENKQIALGTSKLNYLDPRITVAWCKKWGVPIEK

Rat                           EVQATDREENKQIALGTSKLNYLDPRITVAWCKKWGVPIEK

Xenopus laevis                EVQATDREENKQIALGTSKLNYLDPRISVAWCKKYGVPIEK

Caenorhabditis elegans        KISRTDKDENKQIALGTSKLNYIDPRITVAWCKKFEVPLEK

Drosophila                    ELQETDRDENKTIALGTSKLNYLDPRISVAWCKKHDVPIEK

Slime mold                    EILKTGKDELKTVALGTSKINYLDPRITVAWCKKNKVPVDK

Baker's yeast                 SIQLKDKEENSQVSLGTSKINYIDPRLSVVFCKKYDVPIEK

Fission yeast                 RTQMIDKDENKTTALGTSKINYIDPRLTYSFSKREDVPIEK

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	2 – 765	DNA topoisomerase 1
Domain	432 – 765	Topo IB-type catalytic
Active site	723 – 723	O-(3'-phospho-DNA)-tyrosine intermediate
Cross	712 – 712	Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2)
Mutagenesis	723 – 723	Y -> F. No change in CPT-induced clearing from nuclei.
Turn	721 – 723

Literature citations
Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin.
Fujimori A.; Harker W.G.; Kohlhagen G.; Hoki Y.; Pommier Y.;
Cancer Res. 55:1339-1346(1995)
Cited for: NUCLEOTIDE SEQUENCE [MRNA] OF 5-765; VARIANTS CPT-RESISTANT LEUKEMIA THR-370 AND SER-722;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.